Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy

American Journal of Nephrology

Volumn 37, Issue 5, 2013, Pages 491-500

  Park, Sun Hee ^a   Hyun, Seung Hyea ^a   Ryu, Hye Myung ^a   Ahn, Ji Sun ^a   Oh, Se Hyun ^a   Oh, Eun Joo ^a   Yoon, Se Hee ^a   Choi, Ji Young ^a   Cho, Jang Hee ^a   Kim, Chan Duck ^a   Kim, Yong Lim ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Albuminuria; Endothelial dysfunction; Nephropathy; Proximal tubular cells

Indexed keywords

ACETYLGLUCOSAMINIDASE; ALBUMIN; ANGIOTENSIN II; DEOXYGUANOSINE; DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 1; LOSARTAN; N(G),N(G) DIMETHYLARGININE; PENTOXIFYLLINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 8 HYDROXYDEOXYGUANOSINE; MESSENGER RNA; N ACETYL BETA GLUCOSAMINIDASE;

ALBUMINURIA; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; IMMUNOFLUORESCENCE; KIDNEY DISEASE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; DRUG EFFECT; ENZYME RELEASE; PROTEINURIA;

ACETYLGLUCOSAMINIDASE; ALBUMINURIA; AMIDOHYDROLASES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ARGININE; CELL LINE; FREE RADICAL SCAVENGERS; KIDNEY TUBULES, PROXIMAL; LOSARTAN; OXIDATIVE STRESS; PENTOXIFYLLINE; RATS; REACTIVE OXYGEN SPECIES;

EID: 84876795774     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000350541     Document Type: Article

References (27)

1. Warnock DG, Muntner P, McCullough PA, Zhang X, McClure LA, Zakai N, Cushman M, Newsome BB, Kewalramani R, Steffes MW, et al: Kidney function, albuminuria, and allcause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis 2010; 56: 861- 871
2. Yilmaz MI, Sonmez A, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Cakir E, Oguz Y, Vural A, et al: ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol 2008; 19: 388-395
3. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C: Asymmetric dimethylarginine, L -arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518-523
4. Furuki K, Adachi H, Enomoto M, Otsuka M, Fukami A, Kumagae S, Matsuoka H, Nanjo Y, Kakuma T, Imaizumi T: Plasma level of asymmetric dimethylarginine as a predictor of carotid intima-media thickness progression: Six-year prospective study using carotid ultrasonography. Hypertens Res 2008; 31: 1185- 1189
5. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170- 176
6. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C: Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455
7. Young JM, Terrin N, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Sarnak MJ, Menon V: Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1115- 1120
8. Chen MF, Xie XM, Yang TL, Wang YJ, Zhang XH, Luo BL, Li YJ: Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II. J Vasc Res 2007; 44: 391- 402
9. Ono Y, Nakaya Y, Bando S, Soeki T, Ito S, Sata M: Telmisartan decreases plasma levels of asymmetrical dimethyl- L -arginine and improves lipid and glucose metabolism and vascular function. Int Heart J 2009; 50: 73- 83
10. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861- 869
11. Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P: Renal effects of losartan and amlodipine in hypertensive patients with nondiabetic nephropathy. Nephrol Dial Transplant 1998; 13: 3096-3102
12. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
13. Navarro JF, Mora C, Muros M, Garcia J: Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomized, controlled trial. J Am Soc Nephrol 2005; 16: 2119-2126
14. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH: Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004; 27: 765-769
15. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine: A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847
16. Boger RH, Diemert A, Schwedhelm E, Luneburg N, Maas R, Hecher K: The role of nitric oxide synthase inhibition by asymmetric dimethylarginine in the pathophysiology of preeclampsia. Gynecol Obstet Invest 2010; 69: 1-13
17. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, et al: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 2001; 358: 2113-2117
18. Boger RH, Bode-Boger SM, Brandes RP, Phivthong-ngam L, Bohme M, Nafe R, Mugge A, Frolich JC: Dietary L -arginine reduces the progression of atherosclerosis in cholesterolfed rabbits: Comparison with lovastatin. Circulation 1997; 96: 1282-1290
19. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, Tsao PS, Kimoto M, Vallance P, Patterson AJ, et al: Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence. Circulation 2003; 108: 3042-3047
20. Maas R: Pharmacotherapies and their influence on asymmetric dimethylarginine. Vasc Med 2005; 10(suppl 1):S49-S57
21. Luo Z, Teerlink T, Griendling K, Aslam S, Welch WJ, Wilcox CS: Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells. Hypertension 2010; 56: 498-504
22. Giatras I, Lau J, Levey AS: Effect of angiotensinconverting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Angiotensin-Converting- Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997; 127: 337-345
23. Davids M, Richir MC, Visser M, Ellger B, van den Berghe G, van Leeuwen PA, Teerlink T: Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness. Metabolism 2012; 61: 482-490
24. Chen GF, Moningka NC, Sasser JM, Zharikov S, Cunningham M Jr, Tain YL, Schwartz IF, Baylis C: Arginine and asymmetric dimethylarginine in puromycin aminonucleoside-induced chronic kidney disease in the rat. Am J Nephrol 2012; 35: 40-48
25. Hu X, Xu X, Zhu G, Atzler D, Kimoto M, Chen J, Schwedhelm E, Luneburg N, Boger RH, Zhang P, et al: Vascular endothelial-specific dimethylarginine dimethylaminohydrolase- 1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation 2009; 120: 2222-2229
26. Leiper J, Murray-Rust J, McDonald N, Vallance P: S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002; 99: 13527-13532
27. Tain YL, Baylis C: Determination of dimethylarginine dimethylaminohydrolase activity in the kidney. Kidney Int 2007; 72: 886-889 & Welfare